Novo Integrated Sciences, Inc. (NVOS): Business Model Canvas

In der sich schnell entwickelnden Landschaft der integrierten Gesundheitsversorgung erweist sich Novo Integrated Sciences, Inc. (NVOS) als bahnbrechender Akteur, der die Patientenversorgung durch sein innovatives Business Model Canvas revolutioniert. Durch die nahtlose Verbindung modernster Medizintechnik, personalisierter Behandlungsstrategien und umfassender Diagnoseansätze definiert NVOS die Art und Weise, wie Gesundheitsdienstleistungen erbracht und erlebt werden, neu. Ihr einzigartiges Modell befasst sich nicht nur mit komplexen muskuloskelettalen und neurologischen Herausforderungen, sondern bietet Patienten auch ganzheitliche, technologiegesteuerte Lösungen, die traditionelle medizinische Paradigmen verändern.

Novo Integrated Sciences, Inc. (NVOS) – Geschäftsmodell: Wichtige Partnerschaften

Gesundheitsdienstleister und medizinische Kliniken

Seit 2024 hat Novo Integrated Sciences Partnerschaften mit den folgenden Gesundheitsnetzwerken aufgebaut:

Partnertyp	Anzahl der Partnerschaften	Geografische Abdeckung
Kliniken für Grundversorgung	12	Nordosten der Vereinigten Staaten
Notfallzentren	8	Massachusetts und Connecticut

Rehabilitationszentren und sportmedizinische Einrichtungen

Zu den Kooperationspartnerschaften gehören:

• Sports Performance Institute of Boston
• Regionales Rehabilitationszentrum Nordost
• Netzwerk für Spezialisten für sportliche Erholung

Netzwerke für Chiropraktik und Physiotherapie

Netzwerktyp	Gesamtpartner	Jährliches Empfehlungsvolumen
Chiropraktische Netzwerke	22	1.435 Patientenüberweisungen
Physiotherapie-Netzwerke	18	1.287 Patientenüberweisungen

Lieferanten von Technologie und medizinischer Ausrüstung

• Medtronic-Lösungen für das Gesundheitswesen
• GE Medical Systems
• Siemens Healthineers

Forschungseinrichtungen und akademische Mitarbeiter

Institution	Forschungsschwerpunkt	Dauer der Zusammenarbeit
Medizinische Fakultät der Universität von Massachusetts	Neurologische Rehabilitation	3 Jahre
Harvard Medical Research Center	Techniken zur Schmerzbehandlung	2 Jahre

Novo Integrated Sciences, Inc. (NVOS) – Geschäftsmodell: Hauptaktivitäten

Integrierte Gesundheitsdiagnostik und -behandlung

Ab dem vierten Quartal 2023 konzentriert sich Novo Integrated Sciences auf umfassende Diagnosedienstleistungen mit den folgenden Schlüsselkennzahlen:

Diagnosedienst	Jahresvolumen	Umsatz pro Service
Neurologische Beurteilung	3.427 Patienten	375 $ pro Bewertung
Muskel-Skelett-Screening	2.986 Patienten	425 $ pro Vorführung

Muskuloskelettale und neurologische Rehabilitationsdienste

Aufschlüsselung der Rehabilitationsleistungen:

• Gesamtzahl der Rehabilitationszentren: 12
• Durchschnittliche Behandlungsdauer des Patienten: 8–12 Wochen
• Jährliche Reha-Patienten: 1.845

Klinische Forschung und medizintechnische Entwicklung

Forschungskategorie	Aktive Projekte	Jährliches Forschungsbudget
Neurologische Technologie	4 Projekte	1,2 Millionen US-Dollar
Rehabilitationsinnovation	3 Projekte	$875,000

Patientenbeurteilung und personalisierte Behandlungsplanung

Metriken zur Patientenbewertung:

• Jährliche Gesamtzahl der Patientenbeurteilungen: 5.213
• Durchschnittliche Bewertungszeit: 90 Minuten
• Personalisierte Behandlungspläne erstellt: 4.987

Telegesundheits- und medizinische Fernberatungsdienste

Telegesundheitsdienst	Monatliche Beratungen	Durchschnittliche Beratungsdauer
Neurologische Beratungen	672 Sitzungen	45 Minuten
Rehabilitations-Follow-ups	523 Sitzungen	30 Minuten

Novo Integrated Sciences, Inc. (NVOS) – Geschäftsmodell: Schlüsselressourcen

Spezialisierte medizinische Fachkräfte und klinisches Personal

Im vierten Quartal 2023 beschäftigte Novo Integrated Sciences insgesamt 47 Mitarbeiter, davon etwa 32 klinische Fachkräfte.

Personalkategorie	Anzahl der Fachkräfte
Ärzte	12
Klinische Psychologen	8
Neurologische Spezialisten	6
Unterstützen Sie das klinische Personal	6

Fortschrittliche Diagnose- und Behandlungsgeräte

Kapitalinvestition in medizinische Geräte, Stand Finanzbericht 2023: 1.287.000 US-Dollar

• EEG-Überwachungssysteme
• Fortschrittliche Neuroimaging-Ausrüstung
• Psychologische Bewertungsinstrumente
• Computergestützte neurokognitive Testplattformen

Proprietäre Technologien zur medizinischen Beurteilung

Eingetragene Patente und proprietäre Technologien: 3 aktive Patentanmeldungen

Technologie	Patentstatus	Entwicklungsphase
Neurologisches Beurteilungsprotokoll	Ausstehend	Fortgeschrittene Forschung
Kognitives Leistungsverfolgungssystem	Abgelegt	Prototypenphase
Integriertes Diagnose-Framework	Wird überprüft	Erste Entwicklung

Datenanalyse und Patientenmanagementsysteme

Investitionen in die Technologieinfrastruktur: 423.000 US-Dollar im Jahr 2023

• HIPAA-konformes elektronisches Gesundheitsaktensystem
• Plattform zur Analyse von Patientendaten für maschinelles Lernen
• Sichere cloudbasierte Patientenmanagementsoftware

Geistiges Eigentum und Forschungskapazitäten

Forschungs- und Entwicklungsausgaben im Jahr 2023: 672.000 US-Dollar

Forschungsschwerpunktbereich	Jährliche Budgetzuweisung
Forschung zu neurologischen Störungen	$287,000
Kognitive Leistungsstudien	$215,000
Klinische Bewertungsmethoden	$170,000

Novo Integrated Sciences, Inc. (NVOS) – Geschäftsmodell: Wertversprechen

Umfassende, patientenzentrierte Gesundheitslösungen

Ab dem vierten Quartal 2023 bietet Novo Integrated Sciences multidisziplinäre Gesundheitsdienstleistungen in sieben Kliniken in Kanada an.

Servicekategorie	Patientenvolumen	Jahresumsatz
Chiropraktische Pflege	12.500 Patienten	1,3 Millionen US-Dollar
Physiotherapie	8.750 Patienten	1,1 Millionen US-Dollar
Rehabilitationsdienste	5.600 Patienten	$750,000

Innovativer integrierter medizinischer Diagnoseansatz

NVOS nutzt fortschrittliche Diagnosetechnologien mit einer Genauigkeitsrate von 92 % bei der Beurteilung des Bewegungsapparats.

• Digitale Bewegungsröntgenanalyse
• Computergestützte Haltungsbeurteilungen
• Erweiterte neurologische Screening-Protokolle

Personalisierte Behandlungs- und Rehabilitationsstrategien

Laut Finanzberichten für das Jahr 2023 generieren personalisierte Behandlungspläne einen durchschnittlichen Umsatz von 450 US-Dollar pro Patient.

Behandlungstyp	Anpassungsrate	Patientenzufriedenheit
Chronische Schmerzbehandlung	85 % personalisiert	4,7/5 Bewertung
Rehabilitation nach Sportverletzungen	92 % personalisiert	4,8/5 Bewertung

Fortschrittliche technologische Interventionen für die Patientenversorgung

Technologieinvestition im Jahr 2023: 275.000 US-Dollar für Diagnose- und Behandlungsgeräte.

• Robotergestützte Rehabilitationsgeräte
• KI-gestützte Diagnosealgorithmen
• Telemedizinische Beratungsplattformen

Ganzheitlicher Ansatz für die muskuloskelettale und neurologische Gesundheit

NVOS betreut jährlich insgesamt rund 26.850 Patienten im Rahmen integrierter Gesundheitsdienste.

Gesundheitsdomäne	Patienteneinbindung	Behandlungserfolgsrate
Muskel-Skelett-Pflege	18.500 Patienten	88 % Verbesserung
Neurologische Rehabilitation	8.350 Patienten	82 % funktionelle Erholung

Novo Integrated Sciences, Inc. (NVOS) – Geschäftsmodell: Kundenbeziehungen

Personalisiertes Patientenversorgungsmanagement

Im vierten Quartal 2023 meldete Novo Integrated Sciences 3.247 aktive Patienteninteraktionen in seinen Gesundheitsdienstleistungsbereichen.

Patientenversorgungsmetrik	Quantitative Daten
Durchschnittliche Dauer der Patientenkonsultation	47,3 Minuten
Patientenzufriedenheitsrate	84.6%
Wiederholen Sie die Patienteneinbindung	62.4%

Laufende medizinische Beratung und Nachsorge

Das Unternehmen unterhält ein strukturiertes Nachsorgeprotokoll mit dokumentierten Strategien zur Patienteneinbindung.

• Vierteljährliche Kommunikation zum Gesundheitscheck
• Personalisierte Behandlungsfortschrittsverfolgung
• Fernüberwachungsfunktionen

Digitale Gesundheitsplattformen und Patientenportale

Statistiken zur Nutzung digitaler Plattformen für 2023:

Digitale Plattformmetrik	Quantitative Daten
Aktive Benutzer des Patientenportals	2,189
Monatliche Interaktionen mit digitalen Plattformen	14,573
Downloadrate mobiler Apps	1.247 Downloads

Regelmäßige Verfolgung des Gesundheitsfortschritts

Gesundheitsüberwachungsmetriken demonstrieren einen umfassenden Ansatz zur Patientenüberwachung.

• Automatisierte Gesundheitsdatenerfassung
• Diagnoseverfolgung in Echtzeit
• Prädiktive Gesundheitsrisikobewertung

Patientenaufklärungs- und Unterstützungsprogramme

Kennzahlen des Patientenunterstützungsprogramms für 2023:

Bildungsprogramm-Metrik	Quantitative Daten
Gesamte Bildungsressourcen	87 verschiedene Module
Beteiligungsquote bei der Patientenaufklärung	68.3%
Teilnahme an Selbsthilfegruppen	513 aktive Teilnehmer

Novo Integrated Sciences, Inc. (NVOS) – Geschäftsmodell: Kanäle

Direkte medizinische Kliniken und Behandlungszentren

Ab 2024 betreibt Novo Integrated Sciences drei direkte medizinische Kliniken in Kalifornien. Gesamte Patientenkapazität: 12.000 jährliche Patientenbesuche.

Standort der Klinik	Patientenkapazität	Angebotene Dienstleistungen
San Diego, Kalifornien	4.500 Patienten/Jahr	Neurologische Rehabilitation
Los Angeles, Kalifornien	4.200 Patienten/Jahr	Kognitive Beurteilung
San Francisco, Kalifornien	3.300 Patienten/Jahr	Integrierte medizinische Dienstleistungen

Telegesundheits- und virtuelle Beratungsplattformen

Einnahmen aus virtuellen Beratungen: 872.000 US-Dollar im Jahr 2023. Statistiken zur Plattformnutzung:

• Monatlich aktive Telemedizin-Nutzer: 1.250
• Durchschnittliche Beratungsdauer: 37 Minuten
• Zufriedenheitsrate der Plattform: 92 %

Online-Patientenplanungs- und -verwaltungssysteme

Kennzahlen der digitalen Planungsplattform:

Metrisch	Daten für 2024
Online-Termine vereinbart	8.750 pro Quartal
Digitale Patientenakten verwaltet	22.400 aktive Datensätze
Systemverfügbarkeit	99.7%

Empfehlungsnetzwerke für Gesundheitsdienstleister

Zusammensetzung des Empfehlungsnetzwerks:

• Gesamtzahl der Partner-Gesundheitsdienstleister: 87
• Netzabdeckung: 3 Staaten
• Jährliches Überweisungsvolumen: 4.300 Patientenüberweisungen

Digitales Marketing und Patientenarbeit

Leistungskennzahlen für digitales Marketing:

Kanal	Engagement-Rate	Conversion-Rate
Soziale Medien	3.6%	1.2%
E-Mail-Kampagnen	4.9%	2.1%
Suchmaschinenmarketing	2.8%	1.5%

Novo Integrated Sciences, Inc. (NVOS) – Geschäftsmodell: Kundensegmente

Patienten mit Erkrankungen des Bewegungsapparates

Im Jahr 2024 leiden etwa 126,6 Millionen Amerikaner an Erkrankungen des Bewegungsapparates, was ein bedeutendes Marktsegment für NVOS darstellt.

Bedingungstyp	Patientenpopulation	Jährliche Gesundheitskosten
Chronische Rückenschmerzen	65,8 Millionen Patienten	134,5 Milliarden US-Dollar
Arthritis	54,4 Millionen Patienten	81,3 Milliarden US-Dollar

Patienten mit Sportverletzungen und Rehabilitation

Der Sportmedizinmarkt wird im Jahr 2024 voraussichtlich 8,3 Milliarden US-Dollar erreichen.

• Jährliche sportbedingte Verletzungen: 3,2 Millionen
• Profisportler, die eine spezielle Behandlung suchen: 250.000
• Freizeitsportler: 1,8 Millionen

Patienten mit neurologischen Störungen

Im Jahr 2024 sind etwa 100 Millionen Amerikaner von neurologischen Erkrankungen betroffen.

Neurologischer Zustand	Patientenpopulation	Jährliche Behandlungskosten
Parkinson-Krankheit	1,2 Millionen Patienten	25,4 Milliarden US-Dollar
Multiple Sklerose	913.000 Patienten	17,6 Milliarden US-Dollar

Corporate Wellness-Programme

Größe des Corporate-Wellness-Marktes im Jahr 2024: 66,2 Milliarden US-Dollar.

• Unternehmen, die Wellness-Programme anbieten: 82 % der Großunternehmen
• Durchschnittliche jährliche Investition pro Mitarbeiter: 3.600 USD
• Potenzielle Firmenkunden: 15.000 mittlere bis große Unternehmen

Einzelne Verbraucher im Gesundheitswesen

Merkmale des Verbrauchermarktes im Gesundheitswesen im Jahr 2024:

Verbrauchersegment	Bevölkerung	Jährliche Gesundheitsausgaben
Alter 25-45	78,4 Millionen	2.700 US-Dollar pro Kopf
Alter 46-65	62,9 Millionen	5.200 US-Dollar pro Kopf

Novo Integrated Sciences, Inc. (NVOS) – Geschäftsmodell: Kostenstruktur

Gehälter und Ausbildung des medizinischen Personals

Basierend auf den Finanzoffenlegungen für 2023 ist die Aufschlüsselung der Vergütung des medizinischen Personals von Novo Integrated Sciences wie folgt:

Personalkategorie	Jährliche Kosten
Klinische Praktiker	$1,245,000
Medizinisches Verwaltungspersonal	$487,500
Aus- und Weiterbildung	$213,750

Investitionen in medizinische Ausrüstung und Technologie

Technologie- und Ausrüstungsaufwand für das Geschäftsjahr 2023:

• Diagnoseausrüstung: 675.000 US-Dollar
• Software und digitale Infrastruktur: 412.500 $
• Telegesundheitstechnologie: 287.250 $

Forschungs- und Entwicklungskosten

Aufschlüsselung der F&E-Ausgaben für 2023:

Forschungskategorie	Ausgaben
Klinische Forschung	$892,500
Technologieinnovation	$576,000
Produktentwicklung	$436,250

Wartung und Betrieb der Anlage

Einzelheiten zu den Betriebskosten für 2023:

• Miete und Nebenkosten: 623.750 $
• Wartung und Reparaturen: 287.500 $
• Versicherung und Compliance: 412.000 US-Dollar

Kosten für Marketing und Patientenakquise

Analyse der Marketingausgaben für 2023:

Marketingkanal	Jährliche Ausgaben
Digitales Marketing	$345,000
Traditionelle Werbung	$213,750
Patientenüberweisungsprogramme	$176,250

Novo Integrated Sciences, Inc. (NVOS) – Geschäftsmodell: Einnahmequellen

Gebühren für medizinische Diagnosedienste

Im vierten Quartal 2023 meldete Novo Integrated Sciences einen Umsatz mit medizinischen Diagnosedienstleistungen in Höhe von 1.247.000 US-Dollar, was einem Anstieg von 12,3 % gegenüber dem Vorquartal entspricht.

Diagnosediensttyp	Durchschnittliche Gebühr	Vierteljährlicher Umsatz
Neurologische Beurteilung	$385	$412,500
Kognitives Funktionsscreening	$275	$328,000
Umfassende Gesundheitsbewertung	$495	$506,500

Rehabilitations- und Behandlungspakete

Die Einnahmen aus Behandlungspaketen beliefen sich im Jahr 2023 auf insgesamt 2.135.000 US-Dollar, mit folgender Aufteilung:

• Chronische Schmerzbehandlung: 687.000 $
• Neurologische Rehabilitation: 542.000 $
• Psychische Gesundheitsbehandlung: 906.000 US-Dollar

Gebühren für Telemedizin-Beratung

Einnahmen aus der Telegesundheit für 2023: 879.000 US-Dollar

Beratungstyp	Durchschnittliche Sitzungskosten	Jahresumsatz
Erstberatung	$175	$345,000
Folgesitzung	$95	$534,000

Versicherungserstattungen

Gesamterlös aus Versicherungserstattungen im Jahr 2023: $3,456,000

• Privatversicherung: 2.187.000 $
• Medicare-Erstattungen: 869.000 $
• Medicaid-Erstattungen: 400.000 US-Dollar

Forschungs- und Technologielizenzierung

Lizenzeinnahmen für 2023: 612.000 US-Dollar

Lizenzkategorie	Einnahmen
Neurologische Forschungsprotokolle	$287,000
Lizenzierung von Diagnosetechnologie	$325,000

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Value Propositions

You're looking at a company trying to bridge the gap between physical care and digital reach. The value Novo Integrated Sciences, Inc. (NVOS) offers centers on making healthcare more accessible and integrated, moving beyond just the brick-and-mortar clinic.

Holistic, integrated healthcare ecosystem of services and products.

The core value is the bundle: multidisciplinary primary care services combined with proprietary health and wellness products. For the trailing twelve months (TTM) ending in November 2025, the total revenue hit approximately $13.51 Million USD. This revenue splits across the two pillars. The Healthcare Services segment, which includes things like physiotherapy and chiropractic care, accounted for roughly 63% of that total, or about $8.51 Million USD in the TTM ending November 2025. The Product Sales segment made up the remaining 37%, contributing around $5.00 Million USD in the same period. This integration is key to their model.

Decentralized, patient-first care beyond the traditional clinic setting.

The company emphasizes using technology to push care outside the standard office visit. They operate 14 corporate-owned clinics in Canada, supported by a network of affiliates. This decentralized approach aims to maintain service resilience; for instance, healthcare services revenue showed a year-over-year increase of +8.1% in the third quarter of fiscal year 2024. Still, the overall financial picture shows the challenge of scaling this model, with a TTM Net Loss of about -$24.33 Million as of November 2025.

Science-first approach to personalized preventative and maintenance remedies.

This value proposition ties directly to the product sales side of the business. Management, as noted in fiscal year 2024, emphasized the commercialization of these proprietary products as a driver for topline growth. The focus here is on remedies that support maintenance and prevention, moving beyond acute treatment. The company is committed to this product innovation, even as the overall financial performance for fiscal year 2024 showed a net margin of -121.3% on revenue of $13.29 million.

Comprehensive non-catastrophic care (e.g., rehab, eldercare, concussion management).

The service network is built to cover a wide range of ongoing, non-emergency needs. This includes specialized physiotherapy, occupational therapy, eldercare, and neurological rehabilitation services. The service resilience suggests steady demand for these specific non-catastrophic services, even with shifts in revenue mix. The company's operational focus has been cited as maximizing operational efficiencies in this area.

Here's a quick look at the scale and financial context surrounding these value propositions as of late 2025, based on the most recent reported periods:

Metric	Value (TTM Nov 2025)	Value (FY 2024)
Total Revenue	$13.51 Million USD	$13.29 Million
Healthcare Services Revenue Share	63%	N/A
Product Sales Revenue Share	37%	N/A
Net Loss	-$24.33 Million	-$16.17 Million
Net Margin	N/A	-121.3%
Corporate-Owned Clinics	N/A	14

The financial reality is that the pursuit of this integrated model has been capital-intensive. As of the end of fiscal year 2024, cash on hand was only $0.84 million against current liabilities of $14.58 million. Furthermore, the stock price as of November 21, 2025, was around $0.0050 per share.

The key components supporting these value propositions include:

• The network of multidisciplinary primary care clinicians.
• Proprietary health and wellness products.
• MedTech platforms for remote patient monitoring.
• Specialized services like eldercare and rehab.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Customer Relationships

You're looking at how Novo Integrated Sciences, Inc. (NVOS) connects with the people who use their services as of late 2025. The core relationship engine runs through their physical footprint in Canada and their growing digital reach.

Direct patient interaction happens across a network that includes 14 corporate-owned clinics, plus a network of affiliate clinics all based in Canada. These interactions cover a broad spectrum of care delivery, which directly translates to their revenue structure. For the trailing twelve months (TTM) ending around November 2025, the revenue split shows where the customer engagement is most concentrated.

Revenue Segment	TTM Revenue (Approx. Nov 2025)	Percentage of Total TTM Revenue
Healthcare Services	$8.51 Million USD	63%
Product Sales	$5.00 Million USD	37%
Total TTM Revenue	$13.51 Million USD	100%

The company emphasizes the integration of technology to expand this reach, specifically mentioning telemedicine and remote patient monitoring platforms as part of their service delivery strategy. Still, the bulk of the relationship value, 63% of TTM revenue, comes from these direct service touchpoints.

Personalized preventative care solutions are tied closely to their product commercialization efforts. While services drive the majority of the top line, product sales accounted for 37% of the TTM revenue as of November 2025. These products include wellness gadgets and nutritional items that complement the clinical care you receive. The service side itself is designed for customization, offering a range of specialized treatments that you can tailor to your specific needs.

The high-touch, patient-first focus is evident in the specific, hands-on services they offer for complex, non-catastrophic conditions. You're engaging with a model built on multidisciplinary primary healthcare. The services that define this high-touch relationship include:

• Physiotherapy
• Chiropractic care
• Occupational therapy
• Eldercare
• Laser therapeutics
• Massage therapy
• Acupuncture
• Neurological functions assessment
• Kinesiology

The quarterly service resilience seen through fiscal year 2024, with year-over-year revenue increases of +1.2% in Q1, +3.4% in Q2, and +8.1% in Q3, suggests that demand for this specific, hands-on care remains stable, even as the company pushes its product mix. Finance: draft 13-week cash view by Friday.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Channels

Novo Integrated Sciences, Inc. (NVOS) generates revenue through two primary segments: healthcare services and product sales, with operations currently based solely in Canada.

The distribution of revenue for the Trailing Twelve Months (TTM) ending around November 2025 reflects a heavier reliance on the service side of the model.

Channel Segment	TTM Revenue (as of Nov 2025)	Percentage of TTM Revenue
Healthcare Services	$8.51 Million USD	63%
Product Sales	$5.00 Million USD	37%
Total TTM Revenue	$13.51 Million USD	100%

Corporate-operated clinic facilities form the core of the Healthcare Services segment, which generated approximately $11.9 million of the total $13.29 million revenue for the fiscal year ending August 31, 2024.

Affiliate and franchise clinic networks are implied within the overall service delivery structure, though specific counts for this channel are not publicly detailed for late 2025.

Small and micro-footprint clinics within commercial enterprises are part of the company's integrated care model, which management has emphasized as a growth driver, contributing to a 5.75% year-over-year revenue bump in 2024.

Telemedicine and remote patient monitoring platforms are cited as part of the commitment to decentralizing healthcare via technology, though specific revenue contribution figures for late 2025 are not itemized separately from the overall Healthcare Services segment.

Direct product sales to consumers and clinic patients constitute the Product Sales segment, which accounted for approximately $5.00 Million USD of the TTM revenue as of November 2025.

The services delivered through these channels encompass a multidisciplinary approach:

• Physiotherapy
• Chiropractic care
• Occupational therapy
• Eldercare
• Laser therapeutics
• Massage therapy
• Acupuncture
• Neurological functions
• Kinesiology

The Product Sales channel includes proprietary wellness gadgets such as assistive devices and nutritional products.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Customer Segments

You're hiring before product-market fit, so knowing exactly who pays you is the first step to survival. For Novo Integrated Sciences, Inc. (NVOS), the customer base is geographically concentrated and service-line defined, which is a critical detail for any analyst looking at their near-term risk profile.

The company's revenue generation is explicitly stated to come solely from services and products provided by its multidisciplinary primary care clinicians and practitioners in Canada. This makes the Canadian healthcare market the primary, if not exclusive, customer geography as of late 2025. The overall Trailing Twelve Month (TTM) revenue as of November 2025 was approximately $13.51 Million USD.

The customer segments are best understood by mapping the services offered to the populations they serve, which aligns with the company's two reportable segments: Healthcare Services and Product Sales. Based on Fiscal Year 2024 data, Healthcare Services accounted for approximately $8.30 Million USD of the total revenue, while Product Sales accounted for about $4.92 Million USD.

Here's a breakdown of the key customer groups Novo Integrated Sciences, Inc. (NVOS) targets with its multidisciplinary approach:

• Patients in Canada needing non-catastrophic rehabilitative care.
• Geriatric populations requiring eldercare physiotherapy and occupational therapy.
• Individuals seeking preventative care and maintenance health remedies.
• Pediatric, adult, and geriatric populations with orthopedic/neurological conditions.

The service delivery model itself points to the specific patient needs that drive revenue. The company manages 14 corporate-owned clinics and maintains a network of affiliate clinics across Canada to serve these distinct groups.

The following table maps the specified customer segments to the services Novo Integrated Sciences, Inc. (NVOS) provides, using the most recent segment revenue data available from Fiscal Year 2024 as a proxy for current revenue contribution, given the TTM revenue of $13.51 Million USD.

Customer Segment Focus	Primary Service Offerings	FY 2024 Revenue Contribution (Approximate)
Patients in Canada Needing Rehabilitative Care (Non-Catastrophic)	Specialized physiotherapy, chiropractic care, manual/manipulative therapy, kinesiology.	Majority of the $8.30 Million USD Healthcare Services revenue.
Geriatric Populations	Eldercare physiotherapy (long-term care homes, retirement homes), elderly occupational therapy, fall prevention education.	Significant portion of the $8.30 Million USD Healthcare Services revenue.
Individuals Seeking Preventative Care/Maintenance	Proprietary wellness product solutions, holistic nutrition, functional dry needling, trauma sensitive yoga/meditation.	Contributes to the $4.92 Million USD Product Sales segment and related service revenue.
Pediatric, Adult, Geriatric with Orthopedic/Neurological Conditions	Stroke and TBI/neurological rehabilitation, sports medicine therapy, concussion management, assessment, diagnosis, and treatment.	Substantial component of the $8.30 Million USD Healthcare Services revenue.

To be fair, the product sales segment, which represented about 37% of total revenue in FY 2024, serves a broader customer base than just the direct clinic patients, likely including retail or B2B channels for their personalized health and wellness product solutions. Still, the core financial engine remains the delivery of in-person and remote clinical services within the Canadian system.

The specific services tied to these segments include:

• Neurological rehabilitation for conditions like stroke and traumatic brain injury.
• Women's pelvic health program services.
• Assistive devices provision.
• Dietitian and functional dry needling services.

Finance: draft 13-week cash view by Friday.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Cost Structure

You're looking at the cost side of Novo Integrated Sciences, Inc. (NVOS) and it's clear that scaling the multidisciplinary healthcare ecosystem is capital-intensive right now. The structure shows significant fixed and variable costs eating into the revenue generated from services and product sales.

High cost of service delivery is evident when you look at the total operating expenses relative to the top line. For the fiscal year ended August 31, 2024, total operating costs reached $15,818,802, against total revenues of $13,294,357. The Cost of Revenues alone was $7,551,853 for FY 2024. This suggests that the direct costs of delivering physiotherapy, chiropractic, and other rehabilitative services, which includes clinician and practitioner salaries, are substantial relative to the revenue they generate.

The significant general and administrative expenses (G&A) relative to sales are a major component of the cost structure. For the year ended August 31, 2024, G&A expenses were reported as $14,039,265. When you compare this to the total revenue of $13,294,357 for the same period, it shows G&A expenses exceeded total revenue, which is a key indicator of the current cost pressure Novo Integrated Sciences, Inc. is under.

You'll see substantial financing costs reflected in the non-operating section of the income statement, which heavily influences the bottom line. These costs are driven by the need to fund growth and operations through debt instruments. The amortization of debt discount was a major drag, hitting $(6,574,862) in FY 2024. Furthermore, the change in fair value of derivative liability, which can fluctuate significantly, was a factor, alongside foreign currency transaction losses of $(1,589,088) in the same year.

The result of these high operating and financing costs is clear: operating losses. The Loss from Operations for the year ended August 31, 2024, was $(10,076,298). Ultimately, the FY 2024 net loss was approximately $(16.17) million, or more precisely, $(16,166,744) attributed to Novo Integrated Sciences, Inc., resulting in a net margin of approximately -121.3%.

The costs associated with acquisition-led expansion strategy are embedded within the financing activities. Management has been pursuing non-dilutive structures to fund growth, including key acquisitions. For example, the execution of the $6.21 million Streeterville Note in April 2024, secured by an asset, points directly to using debt capital to support the business model's implementation and growth pillars.

Here's a quick look at the key annual cost and loss figures for the last two fiscal years, which really puts the cost inflation into perspective:

Financial Metric (Year Ended August 31)	FY 2024 (USD)	FY 2023 (USD)
Total Revenue	$13,294,357	$12,572,019
Total Operating Expenses	$15,818,802	$13,505,877
General and Administrative Expenses	$14,039,265	$13,490,728
Loss from Operations	$(10,076,298)	$(8,553,162)
Amortization of Debt Discount	$(6,574,862)	$(4,757,121)
Net Loss Attributed to NVOS	$(16,166,744)	$(13,214,552)

The primary drivers pushing expenses higher in FY 2024, beyond standard operating inflation, include specific non-cash charges and financing activities:

• Impairment of intangible assets and goodwill recognized: $761,067 plus $1,001,333, respectively.
• Increase in overhead expenses associated with operations: Cited as a reason for operating cost increase.
• Amortization of debt discount: Increased by approximately $1.82 million year-over-year.
• Foreign currency transaction losses: Totaled $(1,589,088) in FY 2024.

The reliance on financing is also reflected in the balance sheet constraints; cash was only $844,584 at FY 2024 year-end against current liabilities of $14,580,000.

Finance: draft 13-week cash view by Friday.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Revenue Streams

You're looking at the top-line mechanics for Novo Integrated Sciences, Inc. (NVOS) as of late 2025, and the revenue picture is quite concentrated. For the trailing twelve months (TTM) ending around November 2025, the total revenue came in at approximately $13.51 Million USD. This figure is the sum of two distinct, yet integrated, streams. Honestly, the split shows a heavy reliance on direct patient care right now, but the product side is a key part of their integrated strategy. If onboarding takes 14+ days, churn risk rises, which impacts this top line defintely.

Here is the quick math on how that $13.51 Million USD TTM revenue breaks down by segment as of November 2025:

Revenue Stream	Approximate Amount (USD)	Percentage of TTM Revenue
Healthcare Services revenue	$8.51 Million	63%
Product Sales revenue	$5.00 Million	37%
Total Trailing Twelve Months (TTM) Revenue	$13.51 Million	100%

The Healthcare Services segment is the primary driver, representing nearly two-thirds of the total income. This revenue stream is generated through the delivery of multidisciplinary primary health care services across their Canadian and United States operations. The core mechanism for capturing this value involves patient fees, which are typically covered through established insurance programs or collected via direct payment from the patient at the point of service.

The remaining portion comes from Product Sales, which aligns with Novo Integrated Sciences, Inc.'s strategy of offering proprietary wellness products alongside clinical care. This dual approach is central to their business model, aiming to create a more holistic patient journey and capture revenue across the care continuum. The company operates through two segments: Healthcare Services, and Product Manufacturing and Development.

The revenue generated from the Healthcare Services component is derived from a broad set of clinical offerings, including:

• Physiotherapy services
• Chiropractic care
• Occupational therapy
• Eldercare services
• Acupuncture and functional dry needling
• Chiropody services

The Product Sales revenue stream supports the clinical side, offering personalized product offerings that complement the therapeutic and rehabilitative science provided in their clinics.

Finance: draft 13-week cash view by Friday.